Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | TLR3 | O15455 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terikalant SCHEMBL30770792 | 1.00 | KCNH2 (1.00) | KCNH2DRD2NPSR1SLC6A4TLR9 | |
| Terikalant SCHEMBL9678648 | 1.00 | KCNH2 (1.00) | KCNH2DRD2NPSR1SLC6A4TLR9 | |
| Terikalant SCHEMBL9772825 | 0.99 | KCNH2 (0.98) | KCNH2DRD2NPSR1SLC6A4TLR9 | |
| SCHEMBL18509377 | 0.94 | KCNH2 (0.89) | KCNH2DRD2ABCB1 | |
| SCHEMBL9014359 | 0.94 | KCNH2 (0.89) | KCNH2DRD2NPSR1TLR9TLR7 | |
| Terikalant SCHEMBL10407782 | 0.92 | KCNH2 (0.84) | KCNH2DRD2ACHEHTR2A | |
| Terikalant SCHEMBL1230246 | 0.92 | KCNH2 (0.84) | KCNH2DRD2ACHEHTR2A | |
| Terikalant SCHEMBL1230245 | 0.92 | KCNH2 (0.84) | KCNH2DRD2ACHEHTR2A | |
| Terikalant SCHEMBL10407783 | 0.92 | KCNH2 (0.84) | KCNH2DRD2ACHEHTR2A | |
| SCHEMBL10407769 | 0.91 | KCNH2 (0.84) | KCNH2DRD2QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007009462-A2 | TREATMENT OF MIGRAINE AND HEADACHES | REGION HOVEDSTADEN V/GLOSTRUP HOSPITAL (DK) | 2007-01-25 | — | — | WO | claimed |
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| EP-3355925-B1 | TREATMENT OF ACUTE TRAUMATIC INJURY | UNIV ROCHESTER (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11897918-B2 | Compositions and methods to increase production | Seqirus UK Limited (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11221329-B2 | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | LIEBER INSTITUTE, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| EP-3131578-B1 | COMPOSITIONS AND METHODS TO INCREASE PRODUCTION | SEQIRUS UK LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| CN-1533274-A | Benzofuranes and their use in treatment of artrial fibrillation | �����ɷ� | 2004-09-29 | — | — | CN | disclosed |
| CN-1523980-A | Pharmaceutical formulations containing an active dispersed in a matrix | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| EP-1408958-A1 | BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION | KARO BIO AB (SE) | 2004-04-21 | — | — | EP | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003009839-A1 | BENZOFURANES AND THEIR USE IN THE TREATMENT OF ATRIAL FIBRILLATION | KARO BIO AB (SE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11221329-B2 | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | KCNQ1, KCNQ2, KCNQ3 | KCNH2 72/4885DRD2 2048/4885NPSR1 449/4885 |
| US-11897918-B2 | Compositions and methods to increase production | MRPL21, CHLSN, MAX | KCNH2 4772/4885DRD2 4750/4885NPSR1 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.